**CLINICAL CASE**

**Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity**

Melissa R Briones, Gabrielle A Morgan, Maria C Amoruso, Bahram Rahmani, Maura E Ryan, Lauren M. Pachman

**ABSTRACT**

The study aimed to document the utility of the absolute number of natural killer cells as a biomarker in paediatric orbital myositis (OM). Extracted data from four children with OM included demographics, laboratory values, imaging and treatment response. Stored sera (−80°C) were tested for IgG4 levels in three cases and antibody to Coxsackie B in two cases. Their first symptom was at 14.4±1.2 years (mean±SD). At diagnosis three had creatine phosphokinase (CPK) of 97.3±44.2, aldolase of 8.5±2.8 (n=2), alanine aminotransferase (ALT) of 13±2.8 (n=2) and aspartate aminotransferase (AST) of 21.3±2.9. IgG4 level was 87.7±66 (normal=8–89 mg/dL); two sera (patients 1 and 4) were positive (>1:8 dilution) for anti-Coxsackievirus antigen B5. The CD3-CD16+CD56+ natural killer absolute count was 96.7±28.7 (lower limit of normal=138), increasing to 163±57.2 with disease resolution in three patients. The fourth patient was followed elsewhere. CT showed involvement of bilateral superior oblique, lateral rectus or the left medial rectus muscles. Treatment included intravenous methylprednisolone, methotrexate (n=2) and other immunosuppressants. Paediatric OM disease activity was associated with initially low absolute CD3-CD16+CD56+ natural killer cell counts, which normalised with improvement. We speculate (1) an infection, such as Coxsackie B virus, may be associated with paediatric OM; and (2) the absolute count of circulating CD3-CD16+CD56+ natural killer lymphocytes may serve as a biomarker to guide medical therapy.

**INTRODUCTION**

Orbital myositis (OM), diffuse or focal inflammatory disease of the extraocular muscles, is rare in children, more typically presenting in the third decade with a female predominance. OM falls into the category of ‘idiopathic orbital inflammation’, formerly orbital pseudotumour, and is one of the juvenile inflammatory myopathies. OM can be idiopathic, but has been reported in systemic diseases, including sarcoidosis, Graves’ disease, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and IgG4-related disease, and may occur following infection. The clinical presentation of OM may include orbital or periorbital pain, impaired ocular movement, diplopia and eyelid swelling. While an acute unilateral presentation is typical, bilateral and recurrent involvement has been described. Paediatric OM differs from adult OM in that bilateral involvement, uveitis and papilloedema are more common in children. Children may present with systemic symptoms including fever, malaise and anorexia. Elevated IgM and IgG Coxsackie antibodies at the onset of OM have been reported. Paediatric orbital inflammatory disorders account for 6%–17% of total reported orbital inflammatory disease activity.

**Key messages**

**What is already known about this subject?**

- Orbital myositis is a rare type of idiopathic orbital inflammation in children.
- In orbital myositis, serum levels of muscle enzymes are often normal and there are no known biomarkers of disease activity.
- Treatment of orbital myositis typically includes corticosteroids and sometimes a steroid sparing agent such as methotrexate.

**What does this study add?**

- In our study we found that absolute number of circulating CD3-CD16+CD56+ natural killer cells paralleled disease activity in children with orbital myositis.

**How might this impact on clinical practice?**

- Our study provides preliminary evidence that the absolute level of CD3-CD16+CD56+ natural killer cells may serve as a disease biomarker and a guide for immunosuppressive therapy in children with orbital myositis.
disorders, of which 8% is OM. Serum levels of muscle enzymes are often normal; there are no known biomarkers of disease activity. However, we had previously observed that the absolute number of natural killer (NK) cells (CD3-CD16+CD56+) was an indicator of immune activity in 55% of children with juvenile dermatomyositis (JDM). The goal of this pilot study was to assess the absolute count of circulating NK cells as a potential guide for immunosuppressive therapy in paediatric OM.

METHODS
After obtaining institutional review board (IRB) approval (IRB# 2014–15728), a retrospective review was performed of patients in the Cure JM Center database at the Ann & Robert H Lurie Children's Hospital of Chicago. Of 511 paediatric inflammatory myopathies, 4 had OM (0.78%). Data collected included age, gender, sex, diagnosis, laboratory values, imaging studies, pathology and treatment response. Duration of untreated disease (DUD) was defined as time (months) from onset of first symptoms to date of the first medication. The absolute levels of CD3-CD16+CD56+ NK cells via flow cytometry were determined using standard methods in the Diagnostic Immunology Laboratory. Residual sera (stored at −80°C) were tested for IgG4 levels and antibody to Coxsackievirus B (two patients).

RESULTS
Subjects
All were Caucasian; two were female. The first symptom onset was at 14.4±1.2 (mean±SD) years; the mean DUD was 0.28±0.26 months at first visit. One child, patient 3, presented after disease resolution (table 1).

Laboratory data
At diagnosis/first visit of the active OM, the following were the laboratory values (n=3 except where noted, mean±SD): CPK: 97.3±44.2 (26–268); aldolase: 8.5±2.8 (>8.5) (n=2); ALT: 13±2.8 (n=2); AST: 21.3±2.9; lactate dehydrogenase (LDH): 176±52.4; erythrocyte sedimentation rate (ESR)=6±4; neopterin: 6.3±0.14 (<10 is abnormal) (n=2); and von Willebrand factor antigen: 133±14.1 (n=2). IgG4 levels were 125 mg/dL for patient 1, 11 mg/dL for patient 2 and 127 for patient 3 (mean IgG4 87.7±66, with normal range=8–89 mg/dL). Myositis-specific antibodies were negative (Oklahoma Research Institute). Patients 1 and 4 had elevated Coxsackievirus B5 antibody titres (both titres 1:16, with negative being <1:8); the remaining two patients' sera were not tested (quanty not sufficient(sera); QNS). The absolute number of circulating CD3-CD16+CD56+ NK cells was 96.7±28.7 at diagnosis/first visit (lower limit of normal=138), increasing to the normal range of 163±57.2 with active disease resolution (figure 1).

Muscle involvement
CT studies documented involvement of left and right superior oblique, left and right lateral rectus, and left medial rectus. One child had multiple orbital muscle abnormalities (table 1).

Clinical course
Patient 1
In March 2007, a 15-year-old human leukocyte antigen (HLA)-B27+ boy was presented with 3 days of left eye swelling and pain, redness, diplopia and ptosis; trauma or injury was denied. He had been treated for chalazion with tobramycin/dexamethasone drops and cefuroxime for possible preseptal cellulitis with worsening symptoms. Family history was positive for ankylosing spondylitis (father). He had mild erythema of the left eyelid with swelling, but no tenderness or drainage. CT of the orbits showed OM of the left superior oblique muscle and no periorbital or intraorbital mass. His dramatic response to oral prednisone (60 mg daily) was followed by a recurrence of OM in April 2007, 1 day after completing his prednisone taper. After reinstitution of oral prednisone with methotrexate added as a steroid sparing agent, he was weaned off all medications and remained asymptomatic.

Patient 2
A 15-year-old boy with a history of right OM 8 months prior was presented in October 2006 with bilateral eye pain (right first, then left), horizontal diplopia with left

Table 1 Cases of paediatric orbital myositis from 2006 to 2012

<table>
<thead>
<tr>
<th>Case</th>
<th>Age at presentation (years)</th>
<th>Gender</th>
<th>Muscle involvement</th>
<th>Treatment modalities</th>
<th>Other systemic diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15.02</td>
<td>M</td>
<td>Left superior oblique</td>
<td>Prednisone, methotrexate</td>
<td>N</td>
</tr>
<tr>
<td>2</td>
<td>15.13</td>
<td>M</td>
<td>Right superior oblique, left superior medial rectus and bilateral lateral rectus muscles</td>
<td>Prednisone, methylprednisolone, adalimumab</td>
<td>Undifferentiated granulomatous disease of ocular muscles</td>
</tr>
<tr>
<td>3</td>
<td>19.67</td>
<td>F</td>
<td>Left medial rectus</td>
<td>Methylprednisolone, prednisone</td>
<td>N</td>
</tr>
<tr>
<td>4</td>
<td>13.93</td>
<td>F</td>
<td>Right lateral rectus</td>
<td>Prednisone, methylprednisolone, methotrexate</td>
<td>N</td>
</tr>
</tbody>
</table>
gaze and headache for 1 month. Physical exam showed left eye proptosis with reactive pupils, intact extraocular muscles and conjunctival injection. CT orbit showed new abnormal enlargement of right superior oblique muscle and left superior medial and lateral rectus muscles. The patient improved with intravenous methylprednisolone (1000 mg daily for 3 days), but eye pain and left proptosis returned and he required additional weekly intravenous steroids and methotrexate. Concurrently, he had a cyst removed from the pinna of his left ear, followed by left Bell’s palsy. Eventual biopsy of ocular muscle was reported as granulomatous change, leading to an evaluation for inflammatory bowel disease, which was negative. This was responsive to a tumour necrosis factor-α inhibitor, after which he had slightly depressed circulating levels of IgG=498 (613–1295) and IgA=37.2 (69–309), but normal IgM=61.7 (53–334) and IgE=6.13 (<192).

Patient 3

In March 2010, a 19-year-old girl came to rheumatology with left knee pain and a history of OM. On exam, she had decreased internal rotation of the left knee. X-ray identified a lytic lesion with sclerotic margin within the posterolateral cortex of the left distal femoral metaphysis. The absolute NK count was normal at 264. The patient had a history of OM. In March 2006, age 15, she had sudden onset of left eye pain, photophobia, horizontal diplopia and redness. Her left eye displayed injected medial sclera, pain with lateral/upward/medial gaze, photophobia and mild proptosis. Diagnosed with cellulitis, she did not improve with antibiotics. Repeat CT documented a left medial rectus rim-enhancing hypodense mass (figure 2). Ophthalmology stopped antibiotics and intravenous methylprednisolone and oral prednisone started with sustained resolution after 1 month of therapy.

Patient 4

A 14-year-old girl with a history of OM was seen in the rheumatology clinic in April 2012. In March 2011, she had a sudden-onset right ocular headache. A CT scan of the orbits showed mild right periorbital soft tissue swelling and bilateral sphenoid sinus disease for which she received amoxicillin/clavulanate; the enlargement of the right lateral rectus muscle improved rapidly with oral prednisone (50 mg daily) with a taper off of steroids 1 month later. In January 2012, she developed recurrent similar symptoms and required another course of prednisone. She had recurrence of disease again in March 2012 and April 2012 and required initiation of methotrexate. At last follow-up (2012), her disease was in remission.

**DISCUSSION**

The presentation of OM can mimic an infectious process such as orbital cellulitis, which can delay proper
surveillance. The absolute NK cell (CD3-CD16+CD56+) number and function is moderately reduced in systemic lupus erythematosus, in children with untreated Graves' disease or other paediatric autoimmune diseases. The presence of IgG antibodies to Coxsackievirus B5 in the two patients with OM tested was intriguing, for elevated neutralising antibodies to Coxsackie B2 and B4 were identified in sera from children with JDM. In this study, NK numbers were consistently depressed during active disease and returned to normal range as the OM responded to therapy. This is preliminary evidence that the absolute level of NK cells may serve as a guide for immunosuppressive therapy in children with OM. A larger study of the role of NK cells in the pathophysiology of OM and their utility as biomarkers of disease activity in paediatric OM is warranted.

Author affiliations
1 Division of Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, USA
2 Pediatrics, Stanly Manne Children’s Research Institute, Children’s Hospital of Chicago; Ann and Robert H. Lurie Children’s Hospital, Chicago, USA
3 Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, USA
4 Department of Medical Imaging, Ann & Robert H Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA
5 Division of Pediatric Rheumatology, Ann and Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, USA

Acknowledgements The submission of this manuscript was facilitated by the expert assistance of Brittany Hrudnick, our senior administrator.

Contributors MRB: Performed the chart review, abstracted the data, performed a PubMed search, compiled the references and wrote the manuscript which has now reviewed for resubmission. GAM: Data manager, retrieved and evaluated the individual data, reviewed and edited the manuscript, and has approved the revision. She prepared the sequential graph of available natural killer cells for the revision. MCA: Project coordinator, prepared the IRB for this study which allowed its execution, arranged for the testing of the residual sera for the IgG4 and Coxsackievirus antibodies. She reviewed the manuscript and approves of the final draft. BR: Ophthalmologist who identified the children with OM and referred them to LP for further investigation. He has reviewed the manuscript and approves of the final draft. MER: Radiologist who selected the appropriate documentation for the OM patient presented. She has reviewed the final draft of the manuscript and has agreed with the changes made. LP: Pediatric rheumatologist with experience in NK cell reactivity in children with JDM. She has seen each of the patients, collected and identified the data to be assessed, reviewed MRB manuscript and has approved the last edition of the manuscript and its figures, which are included.

Competing interests None declared.

Patient consent Patient consent has been obtained from all participants. Detailed consent forms were reviewed and approved by the institutional review board.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Please direct enquiries regarding additional data to the corresponding author.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
REFERENCES